Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232832 | 1.00 | EGFR (0.48) | EGFRLMNAHTTSNCAAOC3 | |
| SCHEMBL2801369 | 0.84 | MAPT (0.45) | LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL2801170 | 0.80 | FBP1 (0.50) | MAPTALDH1A1KMT2A | |
| SCHEMBL4261334 | 0.80 | FBP1 (0.50) | MAPTALDH1A1KMT2A | |
| SCHEMBL4261335 | 0.80 | FBP1 (0.50) | MAPTALDH1A1KMT2A | |
| SCHEMBL13569513 | 0.80 | MAPT (0.49) | MAPTALDH1A1KMT2A | |
| SCHEMBL4264338 | 0.80 | MAPT (0.49) | MAPTALDH1A1KMT2A | |
| SCHEMBL11808459 | 0.79 | ALDH1A1 (0.54) | EGFRLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL13232834 | 0.79 | TSHR (0.46) | LMNAMAPTGAAALDH1A1KMT2A | |
| SCHEMBL4259268 | 0.79 | ALDH1A1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | EGFR 3614/4885LMNA 3216/4885HTT 3520/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | EGFR 3614/4885LMNA 3216/4885HTT 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.